Lung Cancer Diagnosis and Treatment Technology Research Center
Laboratory Research Interest:
1.Technological innovation of precise surgical treatment in thoracic surgery: it carries out clinical and basic scientific research on the mode of lymph node drainage for standardized anatomic segmentectomy. At the same time, we had great interest in non-scarring surgery and natural orifice transluminal endoscopic surgery (NOTES), intervention and ablation treatment of peripheral lung ground glass nodules, and a series of related basic research on this field.
2.Research and development of minimally invasive high-tech diagnostic and therapeutic equipment for thoracic surgery: Relying on the original thoracic surgery robot system, endoscopy system and bronchoscopy system, multi-module diagnosis and treatment functions are added and developed to promote the development of one-stop thoracic surgery specialist diagnosis and treatment robots. Developed the pulmonary nodule positioning technology in the operating room before sublobectomy based on optical navigation and positioning, and developed an instrument tracking system with the characteristics of robot-assisted thoracic surgery to solve the judgment of the depth of field and the tracking of the distance and depth of the surgical tool under weak feedback. Develop a bronchoscope robot system to enable medical staff to remotely control related parts of the bronchoscope.
3.Multi-disciplinary research and data analysis of lung tumors: The occurrence and development of lung tumors involve complex regulation at many levels, such as gene mutations, epigenetic changes, abnormal gene expression, and signal pathway disorders. Using single omics data to analyze pathogenic factors the limitations are becoming more obvious. By standardizing high-throughput omics data from multiple levels and sources, comparing the relevance and differences between different omics data, and then screening and filtering candidate disease factors at different levels based on this internal connection to establish lung Quantitative models of the development of lung tumors; predicting the effects of candidate disease factors through simulation and other means, and changing the levels of factors to predict the treatment effect has become an important development direction in the research of precision treatment of lung tumors. Research provides new ideas and new theoretical basis for early diagnosis and individualized treatment of diseases.
4.Screening and identification of new biomarkers for lung tumors: Molecular markers can realize early diagnosis of tumors and can guide clinical precision treatment. Based on the liquid biopsy technology, the research group screened new biomarkers for lung tumors, including non-coding RNA, circulating DNA, peptides, tumor-specific secreted or shedding proteins from blood, exosomes, etc., looking for clinical diagnosis, curative effect prediction, and Prognostic evaluation value of tumor markers.
5.Lung tumor immunoediting mechanism and immunotherapy: The progress of esophageal cancer is a microscopic ecological evolution process. The formation of new tumors requires not only overcoming the competition between mutant cells but also avoiding the surveillance of the immune system. This process follows the natural selection in Darwin's theory of evolution. Due to the heritability of genetic mutations, genetic instability, and differentiation potential of cancer stem cells, esophageal cancer provides a large amount of material for "immune selection", allowing tumors to escape through various mechanisms. From the simple loss of tumor immunogenicity to the active suppression of the host immune system by the tumor, studying the mechanism of esophageal cancer immunoediting will lay the foundation for the immunotherapy of esophageal cancer. In addition, conduct research on the application of immune checkpoint inhibitors, oncolytic viruses, chimeric antigen receptor T cells, and toll-like receptor agonists to relieve tumor immunosuppression, and provide a basis for formulating esophageal cancer immunotherapy programs, thereby effectively improving Treatment results for cancer patients.
There are 36 physicians in the center, including 5 chief physicians, 5 associate chief physicians, 26 fellows and residents, and 1 laboratory staff.
The person in charge of the center is the chief scientist of the "13th Five-Year" national key research and development plan, Zhejiang University Qiushi Distinguished Physician, the director of Zhejiang Lung Tumor Diagnosis and Treatment Technology Research Center, the chairman of the Chest Surgery Branch of the Zhejiang Medical Association, and the Zhejiang Preventive Medicine Association for Lung Cancer Director of the Prevention and Control Committee.
The center has 1 professor, 1 doctoral supervisor and 5 master supervisors. More than 70 masters, doctors and international students have been trained.
Clinical and Scientific Research
The center undertakes the research of the "13th Five-Year Plan" national key research and development project "Construction and Application Research of Medical Endoscope Evaluation System" (project number: 2017YFC0113500), as well as 10 projects from the National Natural Science Foundation of China and more than 10 projects from the Natural Science Foundation of Zhejiang Province , Zhejiang Province Key R&D Program, Zhejiang Province Major Science and Technology Special Program Projects and more than 60 various scientific research projects.
Scientific Research Outcomes：
The center has successively published more than 200 papers of various kinds in domestic and foreign magazines, of which more than 100 have been included in SCI. He has published more than 20 papers in high-impact journals such as J Thorac Cardiov Surg, Ann Thorac Surg, Eur J Cardiothorac Surg, TOP journals of thoracic surgery; among them, "A transformative tale of patients and doctors in China" was included in "Lancet" magazine.
The center edited monographs "Minimally Invasive Pulmonary Surgery", "Esophageal Cancer Nutritional Treatment", translated "New Advances in the Diagnosis and Treatment of Lung Cancer", "Atlas of Minimally Invasive Surgery for Esophageal Cancer", and participated in the compilation of the five-year and seven Compilation of annual and eight-year textbooks and standardized training textbooks for residents of the National Health and Family Planning Commission.
More than 10 patents have been authorized, including 2 invention patents.
The Second Prize of the Chinese Medical Science and Technology Award, the establishment, promotion and application of key technologies for robotic assisted surgery in Chinese thoracic surgery.
The Second Prize of Science and Technology Progress Award of the Ministry of Education, key technology innovation and clinical application in comprehensive diagnosis and treatment of lung cancer.